Publications by authors named "F Nagase"
To examine whether extending tocilizumab (TCZ) intervals is a feasible treatment strategy in giant cell arteritis (GCA). This multicenter retrospective study included patients with GCA who started subcutaneous TCZ at five Japanese hospitals between January 2008 and July 2021. We collected clinical data and monitored relapses for up to 24 months following the initiation of TCZ.
View Article and Find Full Text PDFBackground: The optimal treatment for profound hyponatraemia remains uncertain. Recent clinical studies have demonstrated that a standardized bolus of hypertonic saline is effective, but relying solely on this approach may not fully address the individual variability of hyponatraemia among patients. We evaluated the effectiveness of rapid bolus (RB) administration of hypertonic saline followed by predictive correction (PC) using an infusate and fluid loss formula identical to the Barsoum-Levine formula based on the Edelman equation (RB-PC) for managing profound hyponatraemia.
View Article and Find Full Text PDFArticle Synopsis
- Tocilizumab (TCZ) is an effective treatment for giant cell arteritis (GCA), but its impact on treatment changes and outcomes following relapses or discontinuations due to adverse events (AEs) is not well studied.
- In a retrospective study of 62 GCA patients receiving TCZ, 16% experienced relapses, often after dosage adjustments or stopping TCZ; most relapses were manageable with treatment modifications.
- About 45% of patients experienced AEs, with a small portion discontinuing TCZ; those who used alternative immunosuppressive therapies had better outcomes in managing GCA and avoiding relapses.
Article Synopsis
- Water diuresis complicates the treatment of profound hyponatremia, often appearing within the first 24 hours of therapy alongside shifts in urine characteristics.
- Monitoring urine output and composition during early treatment is crucial for promptly identifying this condition.
- In a study of 47 patients, 64% exhibited water diuresis, primarily due to various causes, with significant changes in urine volume and electrolytes noted shortly after treatment initiation.
Article Synopsis
- * A renal biopsy revealed damage likely caused by pemetrexed, leading to its withdrawal, but her kidney function continued to decline.
- * A second biopsy indicated severe acute kidney inflammation from pembrolizumab, highlighting the need to be cautious about kidney toxicity when combining immunotherapies with chemotherapy.